Mark Foster Mark.foster@mdsas.com Replace this photo with your own by going to Insert  Photo  Picture from File.

Number of patients treated by year

Recorded yearly usage

Year % Increase Usage 2011/12 13% 2012/13 11% 2013/14 15% 2014/15 16%

Average yearly usage

Number of patients treated by region

Yearly Usage by Region

Average patient usage by region

Number of patients treated by Speciality

Yearly Usage by Speciality

Average patient usage by speciality

Average patient usage - Haematology Condition Grams 14/15 ITP Acute 222,526 ITP Persistent 54,140

Average patient usage - Immunology Condition Grams 14/15 PID 1,102,219 Secondary 225,344 Specific 46,058

Average patient usage by - Neurology Condition Grams 14/15 CIDP 859,480 MMN 411,494 MG 173,893 GB 142,285 IM 97,308

Average patient usage by indication & regime

Year 2011/12 2012/13 2013/14 20141/15 Grey Usage 263,445 301,859 315,143 354,744

Grey Requests 1028 1404 1424 1331 Outcomes n/a 433 326 307 Percentage Year 2011/12 2012/13 2013/14 20141/15 Grey Requests 1028 1404 1424 1331 Outcomes n/a 433 326 307 Percentage 31% 23%

Yearly usage by product type

Yearly intravenous product usage

Yearly subcutaneous product usage

CIDP Analysis – Patients treated & Recorded Usage

CIDP Analysis – Average Usage

ITP Acute Dosing G per KG Percentage 1g 30% 2g 55% >2g 15%

Diagnosis Criteria Met Percentage Yes 96 % No 0.3% N/A 3.7%

Conclusions Database capturing higher percentage of national usage Usage increasing overall Database can help to identify cost saving opportunities Updated guidelines required as part of national strategy Database now able to accommodate studies into immunoglobulin usage Investigate average use increases

In need of IT Services? info@mdsas.com THANK YOU In need of IT Services? info@mdsas.com

2 Condition analysis

Afternoon session Version 5 run through Version 5 – First look & have your say Dashboards Update